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Abstract
The CCN (CYR61 [Cystein-rich61]/CTGF [connective tissue growth factor]/NOV
[Nephroblastoma overexpressed]) proteins constitute a family of regulatory factors involved in
many aspects of cell proliferation and differentiation. An increasing body of evidence indicates that
abnormal expression of the CCN proteins is associated to tumourgenesis. The multimodular
architecture of the CCN proteins, and the production of truncated isoforms in tumours, raise
interesting questions regarding the participation of each individual module to the various biological
properties of these proteins. In this article, we review the current data regarding the involvement
of CCN proteins in tumourigenesis. We also attempt to provide structural basis for the stimulatory
and inhibitory functions of the full length and truncated CCN proteins that are expressed in various
tumour tissues.
Introduction
The CCN family of genes presently consists of six mem-
bers in human also known as: Cyr61 (Cystein rich 61),
CTGF (Connective Tissue Growth Factor), Nov (Nephrob-
lastoma Overexpressed gene), WISP-1, 2 and 3 (Wnt-1
Induced Secreted Proteins) (Table 1). The CCN acronym
was introduced a decade ago by P. Bork who recognised
that the proteins encoded by Cyr61, CTGF, and NOV were
showing a common multimodular organisation [1] (Fig-
ure 1) with structural motifs resembling Insulin-like
Growth Factor Binding Proteins (IGFBPs), Von Wille-
brand factor, thrombospondin, and secreted growth fac-
tors. The CCN proteins all contain an N-terminal signal
peptide followed by the four structural domains that are
largely conserved among the different members of the
CCN family (Figures 2 and 3). Their general properties
have been extensively reviewed [2–4].
Orthologs of the CCN proteins have been found among
vertebrates from Xenopus to human. The first gene of the
CNN family to be cloned (CCN1 originaly designated
3CH61 and Cyr61), was identified as a growth factor-
inducible immediate-early gene in serum-stimulated
mouse BALB/c 3T3 fibroblasts. Its chicken ortholog (Cef-
10) was cloned as a gene induced following the transfor-
mation of chick embryo fibroblasts by the v-src oncogene
of the Rous Sarcoma Virus (RSV). Human CCN2, origi-
nally designated CTGF, was identified as a mitogen factor
present in the conditioned medium of Human Ombilical
Vein Endothelial Cells (HUVECs). The mouse ortholog of
CCN2 (Fisp12, Fibroblast-inducible secreted protein),
was also isolated as a serum-inducible immediate-early
gene in NIH3T3 fibroblasts. CCN2 is transcriptionally
activated with rapid kinetics in fibroblasts by serum
growth factors and is also highly activated by TGFβ.
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tosis Associated Virus (MAV) in chicken nephroblastomas
that represent a unique model of the Wilm's Tumour. It
was originally designated NOV because it was highly
expressed in all MAV-induced nephroblastomas. The
NOV protein was the first member of the CCN family to
show antiproliferative activity.
Differential hybridisation permitted the isolation the
Elm-1 gene (CCN4) which is expressed in low but not
high metastatic murine melanoma cells. The rat rCop-1
gene (CCN5) was found to be down-regulated in rat
embryo fibroblasts transformed by the cooperation of the
H-ras oncogene and oncogenic mutants of the p53 tumor
suppressor gene. CCN4 and CCN5 were subsequently
shown to be induced by the Wnt oncogene and were
therefore designated WISP (Wnt Induced Secreted
Proteins). CCN6 was identified as an Expressed Sequence
Tag (EST), and was shown to be a Wnt responsive gene.
The CCN genes encode secreted proteins associated with
the Extracellular Matrix (ECM) and cell membrane.
Results obtained over the past decade have indicated that
CCN proteins are matricellular proteins which are
involved in the regulation of various cellular functions
which include: proliferation, differentiation, survival,
adhesion and migration. They are expressed in derivatives
of the three embryonic sheets and are implicated in the
development of kidney, nervous system, muscle, bone
marrow, cartilage and bone. During adulthood, they are
Multimodular structure of the CCN proteinsFigure 1
Multimodular structure of the CCN proteins. SP, Signal Peptide ; IGFBP, Insulin-like Growth Factor Binding Protein-like module ; 
VWC, Von Willebrand Factor-like module ; TSP1, Thrombospondin-like module ; CT, cystein knot containing family of growth 
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Table 1: The CCN family of proteins
Other Names
CCN1 CYR61, Cef10, IGFBP-rP4, bIG-M1, IGFBP10
CCN2 CTGF, Fisp12 IGFBP-rP2, Hcs24, IGFBP8, HBGF-0.8, 
ecogenin
CCN3 NOV, IGFBP-rP3, IGFBP9
CCN4 WISP-1, Elm1
CCN5 WISP-2, Cop-1, CTGFL, CTGF-3, HICP
CCN6 WISP-3Page 2 of 15
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Alignment of CCN protein sequences. Alignments were performed with the " interalign " program. Conserved residues have been 
indicated on a black box. Grey boxes indicate positions where more than one amino acid residue is conserved among the 
CCN proteins. Conserved cysteins are indicated in the yellow boxes.
CONSENSUS                         RCLCLVFTLLHL
CCN3(NOV)         1 mqsvqstsfclrk QCLCLTFLLLHL lgqvaat                  32
CCN2(CTGF)        1 mtaasmgpv R VAFVV LLAL csrpavg                  26
CCN1(CYR61)       1 mssria RALALVVTLLHL trlalst                  23
CCN4(WISP1/ELM1)  1 mrwflpwtlaavt              aaaastvlatalspapttmdftp  36
CCN5(WISP2/COP1)  1 mrgtp         KTHLLAFSLLCL lskvrt                   23
CCN6(WISP3)       1 mqgllfstlllag laqfccrvqgtgpldttpegrpg  36
CONSENSUS                      QFCP     PCRCP QPPPRCPPGVSLVLDGCGCCKVCA
CCN3(NOV)        33 QRCP pqc PGRCP ATPPTCAPGVRAVLDGCSCCLVCA  68
CCN2(CTGF)       27 QNCS g PCRCPdEPAPRCPAGVSLVLDGCGCCRVCA  61
CCN1(CYR61)      24 STCP a   ACHCP LEAPKCAPGVGLVRDGCGCCKVCA  57
CCN4(WISP1/ELM1) 37 apledtssrp QFCK w PCECP PSPPRCPLGVSLITDGCECCKMCA  80
CCN5(WISP2/COP1) 24 QLCP t PCTCP WPPPRCPLGVPLVLDGCGCCRVCA  57
CCN6(WISP3)      37 evsdapqrk QFCH w PCKCP QQKPRCPPGVSLVRDGCGCCKICA  79
CONSENSUS           KQLGESCSEADPCDPH KGLYCDYGADRP RY TGVCCA    VE GAGC
CCN3(NOV)        69 RQRGESCSDLEPCDES SGLYCDRSAD PsNQ TGICTA VE GDNC  110
CCN2(CTGF)       62 KQLGELCTERDPCDPH KGLFCDFGSPAN RK IGVCTA    KD GAPC  103
CCN1(CYR61)      58 KQLNEDCSKTQPCD HtKGLECNFGASST AL KGICRA q  SE GRPC  100
CCN4(WISP1/ELM1) 81 QQLGDNCTEAAICDPH RGLYCDYSGDRP RYaIGV CA q VV GVGC  123
CCN5(WISP2/COP1) 58 RRLGEPCDQLHVCDAS QGLVCQPGA GP GG RGALCL l  AEdDSSC  100
CCN6(WISP3)      80 KQPGEICNEADLCDPH KGLYCDYSVDRP RYeTGV CA yl V  AVGC  122
CONSENSUS           EFNGVIYRNGESFQPNCKYQCTCIDGAIGCVPLC    DVRLPNPDCPHP
* *
CCN3(NOV)       111 VFDGVIYRSGEKFQPSCKFQCTCRDGQIGCVPRC ql DVLLPEPNCPAP  158
CCN2(CTGF)      104 IFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLC sm DVRLPSPDCPFP  151
CCN1(CYR61)     101 EYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLC pq ELSLPNLGCPNP  148
CCN4(WISP1/ELM1)124 VLDGVRYNNGQSFQPNCKYNCTCIDGAVGCTPLC l  RVRPPRLWCPHP  170
CCN5(WISP2/COP1)101 EVNGRLYREGETFQPHCSIRCRCEDGGFTCVPLC se DVRLPSWDCPHP  148
CCN6(WISP3)     123 EFNQVHYHNGQVFQPNPLFSCLCVSGAIGCTPLF ip               158
CONSENSUS           RRVEVPGKCCEEWVC  DED
CCN3(NOV)       159 RKVEVPGECCEKWICgpDEE dslggltlaayrpeatlgvevsdssv     204
CCN2(CTGF)      152 RRVKLPGKCCEEWVC DEP kdqtvvgpalaayrledtfgpdptmira   197
CCN1(CYR61)     149 RLVKVTGQCCEEWVC DED sikdpmedqdgllgkelgfdaseveltrn  195
CCN4(WISP1/ELM1)171 RRVSIPGHCCEQWVC  EDD akrprktaprdtgafdavgeveawhr     214
CCN5(WISP2/COP1)149 RRVEVLGKCCPEWVC  GQG gglgtqplpaqgpqfsglvsslppgv     192
CCN6(WISP3)     159                      klagshcsgakggkksdqsncslepllqq  187Page 3 of 15
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Alignment of CCN protein sequences. Alignments were performed with the " interalign " program. Conserved residues have been 
indicated on a black box. Grey boxes indicate positions where more than one amino acid residue is conserved among the 
CCN proteins. Conserved cysteins are indicated in the yellow boxes.
CONSENSUS                                            NCIVQTTEWSPCSKTCG
CCN3(NOV)       205 NCIEQTTEWTACSKSCG  221
CCN2(CTGF)      198 NCLVQTTEWSACSKTCG  214
CCN1(CYR61)     196 neliavgkgsslkrlpvfgmeprilynplqgq KCIVQTTSWSQCSKTCG  244
CCN4(WISP1/ELM1)215 NCIAYTSPWSPCSTSCG  231
CCN5(WISP2/COP1)193                                  PCPEWSTAWGPCSTTCG  209
CCN6(WISP3)     188 lstsyktmpayrnlpliwkk KCLVQATKWTPCSRTCG  224
CONSENSUS           MGISTRVTNENAQCRMEKETRLCMVRPC  DQDI     TIK    KGKK
CCN3(NOV)       222 MGFSTRVTNRNRQCEMLKQTRLCMVRPC EQEP eqp TDK KGKK  263
CCN2(CTGF)      215 MGISTRVTNDNASCRLEKQSRLCMVRPC EADL ee  NIK KGKK  255
CCN1(CYR61)     245 TGISTRVTNDNPECRLVKETRICEVRPC  GQPV ys  SLK KGKK  285
CCN4(WISP1/ELM1)232 LGVSTRISNVNAQCWPEQESRLCNLRPC DVDI ht  LIK    AGKK  272
CCN5(WISP2/COP1)210 LGMATRVSNQNRFCRLETQRRLCLSRPC       pps     rg       242
CCN6(WISP3)     225 MGISNRVTNENSNCEMRKEKRLCYIQPC DSNI lk TIK ip KGKT  267
CONSENSUS           CLRTKK    KPVKFTFSGCTSTKTYKPKFCGVCMDGRCCTPHKTKTIQV
CCN3(NOV)       264 CLRTKK sl KAIHLQFKNCTSLHTYKPRFCGVCSDGRCCTPHNTKTIQA  311
CCN2(CTGF)      256 CIRTPK is KPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTTLPV  303
CCN1(CYR61)     286 CSKTKK sp EPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKM  333
CCN4(WISP1/ELM1)273 CLAVYQ pe ASMNFTLAGCISTRSYQPKYCGVCMDNRCCIPYKSKTIDV  320
CCN5(WISP2/COP1)243        rs                                           244
CCN6(WISP3)     268 CQPTFQ ls KAEKFVFSGCSSTQSYKPTFCGICLDKRCCIPNKSKMITI  315
CONSENSUS           EFQC P DGETFKKNVMWINTCTCHYNCPNPND
CCN3(NOV)       312 EFQCsP GQIVKKPVMVIGTCTCHTNCPKNNE aflqelelkttrgkm   357
CCN2(CTGF)      304 EFKC P DGEVMKKNMMFIKTCACHYNCPGDND ifeslyyrkmygdma   349
CCN1(CYR61)     334 RFRC E DGETFSKNVMMIQSCKCNYNCPHANE aafpfyrlfndihkfrd 381
CCN4(WISP1/ELM1)321 SFQC P DGLGFSRQVLWINACFCNLSCRNPND ifadlesypdfseian  367
CCN5(WISP2/COP1)245                                   pqnsaf            250
CCN6(WISP3)     316 QFDC PnEG SFKWKMLWITSCVCQRNCREPGD ifs               349Page 4 of 15
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pathologies such as: fibrosis, vascular ailments and
tumourigenesis.
The structural similarity observed between CCN and ECM
proteins, their localisation in the ECM, and their ability to
interact with several types of receptors and regulatory pro-
teins raised the possibility that CCN proteins are adhesive
matricellular proteins which represent a new class of sign-
aling molecule playing a critical role in the regulation of
cell proliferation. The production of abnormal levels of
normal or altered CCN proteins might be associated to or
involved in the initiation and establishment of tumours.
Several shorter CCN isoforms have been described in nor-
mal conditions. Different truncated CCN2 proteins were
detected in biological fluids [[6], Riser, personal commu-
nication] and large amounts of a 30 kDa amino-truncated
CCN3 isoform was detected in the nervous system of the
embryonic rat [7]. In myoblasts, a 30 kDa amino trun-
cated CCN3 isoform was also detected. Upon myotube
differentiation the amount of full length CCN3 increased
while the amount of truncated CCN3 was found to wane
(our unpublished results). Presenly, neither the mecha-
nisms governing the production of these various isoforms,
nor the functional relationship that might exist between
these different isoforms are elucidated.
The disruption of the CCN3 gene in MAV-induced neph-
roblastoma [5] provided the first clue that truncated CCN
proteins were implicated in tumourigenesis, and sug-
gested that the balance between the negative and positive
effects of the full length and truncated CCN3 proteins
were critical for normal cell proliferation. These observa-
tions raised the possibility that structural post-transla-
tional modifications of other CCN proteins might also
occur and be critical for their biological properties. In
addition, subcellular addressing of the CCN proteins
appeared as a key point in these regulatory processes.
In this manuscript we review the current knowledge
regarding the implication of CCN proteins in tumourigen-
esis and attempt to provide structural basis for the stimu-
latory and inhibitory functions of the various CCN
isoforms.
Tumourigenesis and CCN proteins
Original observations which established a role for the
CCN proteins in the control of cell proliferation also sug-
gested that CCN1 and 2 were positive regulators of growth
– whereas, CCN3-5 were negative [2–4].
An increasing body of evidence now suggests that the bio-
logical properties of the CCN proteins is dependent upon
the cellular context and their ability to interact with part-
ners involved in complex signaling pathways [8,9]. Recent
results a) drew a relationship between abnormal CCN
protein expression and tumourigenesis b) indicated that
full length secreted CCN proteins can show an antiprolif-
erative activity, whereas truncated isoforms are likely to
stimulate proliferation and behave as oncogenes.
Association of CCN protein expression with increased 
proliferative activity and tumourigenicity
In agreement with the well documented angiogenic prop-
erties of CCN1, gastric adenocarcinoma cells transfected
with CCN1 gave rise to larger and more vascularised
tumours than parental cells when injected into nude mice
[10].
In primary human breast carcinomas elevated levels of
CCN1, CCN2, and CCN4, but not CCN3 were associated
with more advanced features [11]. Increased CCN1 pro-
tein expression was observed in a large number of primary
breast tumours that were progesterone receptor positive
but estrogen receptor negative – suggesting that it might
be a novel mediator of progesterone activity in breast can-
cer [12]. Invasive breast cancer cell lines expressed high
levels of CCN1 whereas less tumourigenic breast cancer
cells, such as MCF-7, expressed lower; normal breast cells
showed almost none. Forced expression of CCN1 in MCF-
7 cells was sufficient to induce their growth without
anchorage in the absence of estrogen and to form colonies
in matrigel in a αvβ3 integrin-dependent way. The
tumours induced by these cells in ovariectomised athymic
nude mice resembled human invasive carcinomas and
were highly vascularised [13–15]. These observations sug-
gested that CCN1 was involved in the progression to more
advanced stages of breast cancer.
Similarly, serum-stimulated MCF7 cells expressed much
higher levels of CCN5 than the serum-starved and CCN5
expression is highest at S-phase in murine fibroblasts.
Additionally, the expression of CCN5 was upregulated in
Wnt-1 transformed C57MG epithelial cells.
Elevated expression of CCN1 has been detected in pancre-
atic cancers [16] and within invasive breast carcinomas
[13]. The expression of CCN1 was also found to have
increased in several types of paediatric tumours including
angiofibroma, malignant fibrous histiocytoma, infantile
myofibromatosis, and malignant haemangiopericytoma
[4].
An elevated expression of CCN2 has also been detected by
Northern blotting in human invasive mammary ductal
carcinomas [17], dermatofibromas, pyogenic granuloma,
endothelial cells of angiolipomas and angioleiomyomas
[18], and in pancreatic tumours [19]. A study performed
with chondrosarcomas representative of various histolog-Page 5 of 15
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correlated with increasing levels of malignancy [20].
In agreement with CCN2 playing a role in brain tumour
angiogenesis, immunocytochemistry studies indicated
that both glioblastoma tumour cells and proliferating
endothelial cells stained positive for CCN2 [21]. In astro-
cytomas, CCN2 expression was particularly elevated in
high grade tumours, with a marked effect of CCN2 on cell
proliferation. Downregulation of CCN2 expression in
these cells was associated with a growth arrest at the G1/S
transition while over-expression of CCN2 induced a two-
fold increase of the number of cells in the G1 phase. Gene
profiling analysis allowed to identify a set of about 50
genes whose expression might account for the prolifera-
tive activity of CCN2 in these cells [22]. CCN2 was seen in
a higher proportion of mononuclear cells of patients with
acute lymphoblastic leukemia [23].
The expression of CCN3 was correlated to increased pro-
liferative index in the case of prostate and renal cell carci-
nomas [24,25] and higher metastatic potential of the
Ewing's carcinoma cells [26]. In addition to the labelling
of CCN3 in the cytoplasm of acinar epithelial cells, pros-
tate hyperplasia was showing an intense luminal labeling
suggestive of CCN3 secretion in seminal fluid. In prostate
tumour cell lines, expression of CCN3 was detected in the
cytoplasm of three cell lines derived from metastasis to
bone (PC3), brain (DU145) and lymph node (LNCap).
As compared to the level of CCN3 in normal prostates,
gene profiling and qRT-PCR studies established that the
level of CCN3 mRNA was increased around 80 fold in
CR2-TAG mice which express the simian virus 40 large T
antigen under the control of cryptdin-2 promoter ele-
ments [27]; these studies indicated that the expression of
CCN3 was not detected in the neuroendocrine cells. No
expression was detected in normal adult prostate luminal
epithelial PNT1B cells immortalised by SV40-T antigen
[24,28], whereas SV40-T immortalised prostate epithelial
P69 cells were positive for CCN3 expression. These results
suggest that CCN3 expression in these cells might be a
marker for epithelial prostatic cell transformation, rather
than a feature of increased proliferation and point out a
role for CCN3 in the transition from normal to malignant
behaviour.
In Renal Cell Carcinomas (RCCs) which represent 85–
90% of all kidney tumours, a significantly higher level of
secreted CCN3 protein was detected by Western blotting
in the conditioned medium of fast growing tumours [25].
An inverse relationship could be drawn between the
amount of CCN3 secreted by the tumour cells and the
time that was required to establish tumours in vivo and for
them to reach a given size.
About 60% of the osteosarcoma tumours were found pos-
itive for CCN3. Again, an inverse relationship was
observed in these tumours between the levels of CCN3
and alkaline phosphatase – an early marker of osteoblas-
tic differentiation. Consequently, as the expression of
alkaline phosphatase was associated with loss of agres-
siveness of osteosarcoma cells, these results indicate that
in this system, the expression of CCN3 is likely to be asso-
ciated with osteoblasts proliferation and therefore repre-
sent a marker of bad prognosis. It is worth noting that
when injected into chicken embryos, MAV also induces
osteopetrosis – a proliferation of osteoblasts. Whether an
increase of CCN3 expression is also associated to osteo-
petrosis remains to be established.
In the case of Ewing's sarcoma, the levels of CCN3 expres-
sion varied among the different samples tested and the
expression of CCN3 in primary tumours was associated to
a significantly higher risk of developing lung and bone
metastasis. Patients with primary tumours negative for
CCN3 expression did not develop metastasis whereas
50% of the patients with primary tumours staining posi-
tive for CCN3 developed metastasis [26]. The expression
of CCN3 in Ewing's transfected cells was shown to
decrease cellular adhesivity and increase cell motility [29],
two observations that are fully consistent with CCN3
being associated with a high metastatic potential.
CCN4 and CCN6 expression was significantly increased
in most colon adenocarcinomas [30]. Overexpression of
CCN4 induced an accelerated growth and morphological
transformation of NRK-49F fibroblastic cells and cell lines
established after infection by retrovirus contructs express-
ing CCN4 was showing increased tumourigenicity. When
tested ex vivo however, forced expression of CCN4
induced only a slight increase of doubling time and slight
decrease of saturation density on the same cells. Inasmuch
as these cells did not grow without anchorage, the over
expression of CCN4 was not sufficient enough to allievi-
ate the need for proper interactions with the ECM and
attachment.
Altogether, these observations are in favour of CCN pro-
teins playing a positive role in tumourigenesis by provid-
ing the stimulatory effects on cell growth that are required
for the increased lifespan of tumour cells. Whether these
effects are involving a partial or complete abrogation of
apoptotic pathways is an interesting question that
deserves attention. The relationship that was drawn
between increased expression of CCN proteins and
tumourigenicity might also affect the communication of
tumour cells with the surrounding medium, as suggested
by the effects of CCN3 on Ewing's sarcoma cells. By
decreasing the adhesivity of the cells and by providing an
increased ability to migrate and invade surrounding tis-Page 6 of 15
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to the metastatic potential of tumour cells. The identifica-
tion of CCN proteins partners should be very helpful in
establishing whether abnormal interactions with physio-
logical targets are involved in these processes.
Association of CCN protein expression with reduced 
proliferative activity and tumourigenicity
The first evidence indicating that the expression of CCN
proteins in tumours could be associated to differentiation
and growth arrest came from our studies performed with
MAV-induced nephroblastomas and Wilm's Tumours.
The Myeloblastosis Associated Virus (MAV)-induced
avian nephroblastomas constitute a unique model of the
Wilm's Tumour [31], a paediatric tumour affecting
approximately one in 10,000 children [32]. Large quanti-
ties of CCN3 transcripts were detected in all MAV-induced
tumours, whereas in normal post-natal kidney the level of
CCN3 expression was low [5].
Considering that non-acute retrovirus had been reported
to induce tumours by integrating nearby growth regula-
tory genes in the host genome, we postulated that a) the
CCN3 gene was a prefered integration site of MAV within
the host genome and b) in these tumours, the expression
of CCN3 was stimulated by MAV-LTR enhancer sequences
integrated in the vicinity of the CCN3 locus. The use of
Bacterial Artificial Chromosomes (BACs) and Fluorescent
In Situ Hybridization (FISH) allowed us to recently estab-
lish that the CCN3 DNA region is not a preferential site of
integration for MAV (C.L. Li, P. Coullin, C. Auffray, A.
Bernheim, V. Joliot, R. Zoroob and B. Perbal, manuscript
in preparation). Furthermore, the histological analysis of
avian nephroblastomas and the expression pattern of
CCN3 in the developing avian kidney, established that the
MAV target cells express high levels of CCN3 and that ele-
vated levels of CCN3 were detected in the more differen-
tiated tumours (Cherel et al., manuscript in preparation;
Chevalier and Perbal, unpublished data).
Analysis of Wilm's Tumours established that blastemal
cells committed to abnormal differentiation were positive
for CCN3 expression. Tumours with a high degree of stro-
mal components contained the highest levels of CCN3
RNA. In some cases, the quantities of CCN3 RNA were
inversely related to the amount of WT1 RNAs detected in
the same samples [33]; an observation which, at first
glance, was in agreement with the ex vivo downregulation
of CCN3 promoter activity by WT1 [34]. However, studies
performed with a larger panel of samples [35] representa-
tive of sporadic, WAGR and DDS histological types of
tumours raised the possibility that the variations of CCN3
expression resulted from different relative amounts of
WT1 isoforms within these tumours. Similarly, CCN2 –
whose expression is also decreased in Wilm's Tumours,
was reported to be a target of WT1 [36].
In the Wilm's Tumours, expression of CCN3 was also
shown to match striated muscular differentiation. During
the heterotypic differentiation of the blastemal cells that
takes place in these tumours, CCN3 expression was
detected at an earlier developmental stage than desmin
and confocal microscopy also indicated that the CCN3
protein was colocalised with desmin in heterotypic mus-
cular fibres [35]. These observations established the level
of CCN3 expression in these tumours as a marker of het-
erotypic differentiation [35] and suggested for the first
time that overexpression of a CCN protein could also be
associated with tumour cell growth arrest. A strong associ-
ation between CCN3 expression and tumour differentia-
tion was also observed in the case of neuroblastomas,
chondrosarcomas, rhabdomyosarcomas and other musc-
uloskeletal tumours [4,24,37].
In neuroblastomas with poor pronostic features, CCN3
staining was low moderate within the tumour cells,
whereas in tumours with favourable pronostic and no N-
myc amplification, the CCN3 staining was strongly
detected in the cytoplasm of differentiated ganglion-type
cells [4]. Immunohistochemistry, Western blotting analy-
sis, and real-time RT-PCR performed on samples from
enchondromas and chondrosarcomas of various grades
also the highest levels of CCN3 expression were detected
in benign enchondromas, and the lowest levels of CCN3
were detected in the tumours of higher grade. Rhabdomy-
osarcomas generally expressed significant amounts of
CCN3, with the largest quantities being detected in the
most differentiated cells [37], an observation in agree-
ment with CCN3 expressed in the developing skeletal
muscle and fusing myoloblasts [38].
A reduction of CCN3 expression in tumour cells was also
observed in the case of human chronic myeloid leukemia
tumours and in murine multipotent haematopoietic stem
cells transfected with a thermo sensitive mutant of the bcr-
abl gene fusion expressed in chronic myeloid leukaemia
(CML) [39]. These results indicated that the tumour-asso-
ciated reduction of CCN3 expression was not a character-
istic specific to solid tumours.
More recently evidence was also obtained for decreased
levels of other CCN proteins in tumours. For example, the
expression of CCN1 was shown to be downregulated in
uterine leiomyomas [40], rhabdomyosarcomas [41], and
in 50% of prostate carcinomas [42]. In non-small cell lung
cancer (NSCLC), the expression of CCN1 was also
decreased markedly, compared to the matched normal
samples [43]. In opposition to the stimulatory effect of
CCN2 on human embryonal carcinoma cell growth, itsPage 7 of 15
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all-trans retinoic acid and were undergoing neuronal
differentiation with concomitant loss of tumourigenicity
[44].
Originally reported to be highly expressed in murine cells
with a low metastatic potential, CCN4 was detected at
similar levels in normal breast epithelial cells and breast
tumour cell lines [45]. In primary human colon adenocar-
cinomas, the expression of CCN5 was significantly
decreased and it was not detected in the epithelial tumour
cells of mammary carcinoma obtained from Wnt-1 trans-
genic mice [30]. CCN5 was also downregulated upon
transformation of BALB/c3T3 fibroblastic cells. The
expression of CCN6 was impaired in most infammatory
breast cancer [46] and a relationship was observed
between loss of function mutations in CCN6 and progres-
sive pseudorheumatoid dysplasia [47].
CCN proteins may act as antiproliferative agents
Not only the amounts of CCN proteins were low in some
tumours, but an increasing body of evidence indicates
that overexpression of CCN proteins in tumour cells may
result in growth arrest and/or reduced tumourigenicity.
For example, early studies indicated that high levels of
CCN3 expression were correlated with reduced tumouri-
gencity and low metastatic potential of glioblastoma cells
[48]. By using a series of stable transfectants, we estab-
lished that CCN3 had a marked antiproliferative effect on
glioblastoma cells [49]. Furthermore, the cells expressing
CCN3 showed a significant reduction in their ability to
induce tumours in nude mice. Inasmuch as the expression
of CCN3 was interfering with tumour expansion, but not
with early stages of tumour developement, we hypothe-
sised that CCN3 might be cooperating with other proteins
at the cell surface or in the ECM to regulate cell prolifera-
tion and invasiveness.
In agreement with these observations, confocal analysis
performed on the transfected cells established that CCN3
and Connexin-43 (Cx-43) were colocalised [49], an obser-
vation raising the possibility that they may physically
interact. Similarly, Cx-43 and CCN3 proteins were colo-
calized at the membrane of choriocarcinoma cells [50].
Inasmuch as an aberrant Gap Junctional Intercellular
Communication (GJIC) was associated to tumourigene-
sis, these results suggested that CCN3 is involved in the
control of cell growth at least through its relationship with
GJIC. Upon restoration of cell to cell communication via
Cx-43 protein channels, human choriocarcinoma cells
lost their ability to induce tumour growth in vitro, and
strongly upregulated the expression of CCN3.
Along the same line, the isolation of stable transfectants
expressing CCN3 under the control of constitutive and
inducible promoters also permitted to establish that
CCN3 was able to significantly reduce the growth rate of
EWS transfectants ex vivo [29]. Interestingly, transfectants
showed reduced adhesivity and increased motility – two
features in agreement with CCN3 expression associated
with higher metastatic potential (see above).
The expression of CCN1 in NSCLC stable transfectants
induced a significant reduction of the proliferation rate
that could be partially rescued after addition CCN1 anti-
bodies. The CCN1 transfected cells where arrested in the
G1 phase of the cell cycle, showed a decreased activity of
CDK2 and an upregulation of p53, p21(WAF1), and
pRB2/p130. Interestingly, the transfected cells expressing
CCN1 gave rise to smaller tumours than those induced by
the parental NSCLC cells [43].
The CCN4 protein was also reported to have marked
inhibitory effects on the tumourigenic properties of
tumour cells in vivo. The absolute number of tumours
obtained was dramatically reduced by the expression of
CCN4 and the time needed for tumours to reach a given
size was considerably higher as a result of the marked
inhibitory effect of CCN4 on the growth properties of
transfected cells in vivo. Furthermore, the transfectants
which expressed high levels of CCN4 gave rise to a much
smaller number of lung metastasis than those expressing
low levels of CCN4. Recently, it was shown that overex-
pression of CCN4 in lung cancer cells reduced their ability
to induce metastasis in nude mice, and impaired their
migration within Boyden chambers in response to serum
[51].
Early results established the antiproliferative activity of
CCN5. Repressed in several transformed derivatives, retro-
viral-driven ectopic expression of CCN5 induced a nega-
tive effect on the growth of rat transformed cells and was
accompanied by an enrichement in subG1 DNA content
[52]. These observations therefore suggested that overex-
pression of CCN5 might induce cell death. Furthermore,
CCN5 overexpression in stably-transfected rat cells trans-
formed by p53 and H-ras, significantly reduced their
tumourigenicity when tested by subcutaneous injection in
athymic mice. The expression of CCN5 was detected only
after repeated passages of rat and mouse embryo
fibroblasts, but not in primary fibroblasts. More recently,
overexpression of CCN5 was reported to inhibit both pro-
liferation and motility of myometrial, leiomyoma smooth
muscle cells and vascular smooth muscle cells [53]. High
levels of CCN5 expression were also detected in quiescent
and heparin-treated vascular smooth muscle cells. [53].Page 8 of 15
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Inflammatory Breast Cancer (IBC) cells resulted in the
induction of morphological changes and a decreased
ability to grow in soft agar. Importantly, the restoration of
CCN6 expression resulted in tumour growth suppression,
but with a decrease of tumour cell growth in grafted nude
mice [54], an observation reminiscent to the effects of
CCN3 on glioblastoma cells (see above).
Collectively, these results indicated that the expression of
CCN proteins was altered in various types of tumours;
depending upon the type of cells and tissues, high levels
of CCN expression could be associated to either differen-
tiation or increased proliferation and metastasis. They
also suggested that CCN proteins may be acting as a
tumour suppressor, irrespective of their pattern of expres-
sion upon serum stimulation. The differential expression
of CCN genes upon serum stimulation previously led to
the conclusion that immediate early genes such as CCN1
and CCN2 were encoding positive growth regulators;
whereas, genes whose expression was not induced or were
repressed by serum were encoding growth suppressors.
Answers lie in the multimodular structure of the 
CCN proteins
We believe that a better understanding of the structural
organisation of the CCN proteins is the key to the under-
standing of their various biological activities. It is worth
pointing that several different signalling proteins have
been shown to physically interact with CCN proteins. For
example, CCN1,2 and 3 interact with a whole array of
Integrins [3,55,56], and CCN3 interacts with Fibulin1C
[57], Notch1 [58] and S100A4 proteins [59]. The exist-
ence of CCN isoforms which are biologically active have
already been proposed to be a key element in regulating
the functions of the CCN proteins [4]. Our current work-
ing model is based on the hypothesis that post transla-
tional modifications of the full length proteins, or
alternative splicing of CCN mRNA species, are giving rise
to CCN isoforms that may show opposite, or synergistic
biological effects, either because their structure dictate dif-
ferent types of protein interaction, and/or because they
are adressed to different subcellular compartments. The
mosaic structure of the CCN proteins raises interesting
questions as to the role and participation of each individ-
ual module to the biological function(s) of the full length
and truncated CCN proteins.
Signal peptide
All CCN genes encode proteins with a signal peptide (fig-
ure 2) that we have recently established to be responsible
for secretion (N. Planque, C.L. Li, L. Dassencourt, E. Ker-
belec, and B. Perbal unpublished). The signal peptide is
encoded by the first exon in the mRNA species encoding
full length proteins.
In one of the MAV1-(N) – induced tumours, integration
of the proviral genome in the CCN3 gene resulted in the
production of a chimeric mRNA species whose translation
gave rise to a 28 kDa CCN3 protein deprived of both the
signal peptide and module I (Figure 4). Over-expression
of this protein by an RSV-based recombinant virus
induced morphological transformation of chicken
embryo fibroblasts [5]. Interestingly, a 31 kDa aminotrun-
cated CCN3 isoform deprived of module I was also
detected in the nucleus of HeLa and 143 osteosarcoma
cells [60,61]. It is therefore tempting to draw a relation-
ship between these observations.
Since the absence of signal peptide in the aminotruncated
isoform was expected to alter the fate of the CCN3 protein
which is otherwise secreted (Figure 5), we proposed that
the transforming potential of the truncated CCN3 protein
results from its migration to the nucleus in RSV infected
cells and in nephroblastoma tumour cells. The interaction
of CCN3 with the rpb7 subunit of RNA polymerase II [60]
promotes the idea that CCN3 might play a role in the con-
trol of transcription. As opposed to the antiproliferative
activity of the full length secreted form (see above), we are
currently investigating this hypothesis and the possibility
that the nuclear isoform of CCN3 is stimulating cell
proliferation.
Other CCN3 isoforms have been identified in the cytosol
of various cell lines [35]. Whether the intracellular expres-
sion of these proteins accounts for the various roles of the
CCN3 protein in signalling remains to be established.
Along the same line, it is worth noting that, extracellular
CCN2 was reported to be transported to the nucleus of
endothelial cells [62] where it was proposed to modulate
transcription.
In a recent study, the use of transfectants isolated from a
human oral squamous cell carcinoma-derived cell line
permitted to show that intracellularly expressed full
length CCN2 was reducing cell growth and tumourigenic-
ity [63]. It would be interesting to determine whether this
observation is specific to CCN2 or whether it also applies
to other members of the CCN family.
Module I (IGFBP)
Module I is encoded by the second exon of the CCN
genes. According to secondary structure prediction
programs, the N-terminus the CCN proteins shows signif-
icant differences among which the presence of β-sheets
specific to CCN3, 4, 5 and 6 might be related to particular
biological function(s).
Module I shares partial identity with the N-terminal part
of the Insulin-like Growth Factor Binding Proteins
(IGFBPs). However, a careful analysis of nucleotidePage 9 of 15
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posed for N-terminal cysteine residues of IGFBPs and
CCN proteins was not appropriate [64]. Because of this
partial sequence identity, it was proposed that CCN pro-
teins bind to IGF. This point remains controversial [65]
and the biological significance of the structural relation-
ship between IGFBPs and CCN proteins is still an open
topic. In vitro crosslinking experiments suggested that full-
length CCN2 and CCN3 could bind to IGF with very low
affinity [66,67], whereas, ligand blotting did not permit
detection of any interaction between CCN3 and IGF [32].
Interestingly, N-terminal truncated forms of CCN2 binds
efficiently to IGF, and the N-terminal region of CCN3
binds to insulin with a much higher affinity than IGFBPs
[68].
Proteolysis of the secreted full length CCN proteins that
has been reported in the case of CCN2 and CCN3
[6,35,57] might result in the production of CCN-derived
peptides with high affinity for ligands that full-length
CNN proteins bind only poorly. Amino-truncated CCN2
isoforms were biologically active whereas no specific bio-
logical activity has been attributed to the truncated CCN3.
Although the molecular processes underlying the produc-
Insertional mutagenesis of MAVFigure 4
Insertional mutagenesis of MAV. The organisation of the chicken CCN3 gene is represented at the top. The CCN3 chicken pro-
tein encode a putative secreted 36 KDa protein. Following post-translational modifications, a full length 41 KDa CCN3 protein 
is released in the culture medium. In one MAV-induced nephroblastoma, proviral sequences were integrated within exon 2 of 
the CCN3 gene. As a consequence, MAV LTR was driving the expression of a chimaeric mRNA species encoding an amino 
truncated CCN3 protein deprived of module I and signal peptide. ORF : open reading frame ; (th) : theoretical ; (s) :secreted. 
The signal peptide (sp) is encoded by exon 1. E1–E5 : exons encoding the CCN3 protein. n201, n318 indicate the boundaries 
of the RNA stretch corresponding to the remaining sequences from exon 2. 91 n : 91 nucleotides of viral origin ; 117 n exon 2 
sequences which are out of frame in the chimaeric mRNA species.
MAV LTR
E1 E2 E3 E4 E5
36 KDa (th)sp 76aa
28 KDa (th)
84aa 70aa 98aa
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important to note that proteolysis occur at the same
amino acid residues in both CCN2 and CCN3 [57].
Module II (VWC)
Module II includes a stretch of 70amino acid residues –
which shares sequence identity with the Von Willebrand
Factor Type C repeat (VWC). It is encoded by exon 3 and
is well conserved among all members of the CCN family
with the exception of CCN6, which lacks four of the 10
cysteine residues contained in this module. The VWC
motif is also present in other secretory proteins such as α-
collagen, thrombospondin 1 and 2, mucins, and Dro-
sophila SOG (Short Gastrulation) protein. In addition to
the VWC motif, exon 3 also encode a region devoid of
cysteines that may serve as a hinge connecting the N- and
C-terminal halves of the proteins. This region is highly
charged and is longer in CCN1 than in the other CCN
members (48aa's versus 10 –15aa's). Secondary structure
predictions shows great structural differences in this
region among the different members of the CCN family.
The variable region of CCN6 only contains α-helix
whereas in the other CCN members it contains β-sheets
and β-turns.
Module II contains sequences that were proposed to drive
protein oligomerisation. Inasmuch as CCN4 protein lack-
ing module II are produced in scirrhous gastric carcinoma
by alternative splicing [69], it would be interesting to
determine whether the deletion of this module alters the
capacity of CCN4 to oligomerise and confers on this
protein new biological properties. Should it be the case,
alternative splicing of VWC sequences would represent an
additional mean to produce oncogenic variant forms of
CCN proteins.
Subcellular localisation of the CCN3 isoforms is critical for biological activityFigure 5
Subcellular localisation of the CCN3 isoforms is critical for biological activity. The cDNA sequences encoding the truncated and the 
full length CCN3 protein were inserted into RCAS non defective Rous sarcoma virus (RSV)-derived proviral vector. The 
amino-truncated CCN3 protein which is deprived of signal peptide (top) is not secreted and induces morphological transfor-
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Module III contains sequences sharing identity with the
Thrombospondin type 1 repeat (TSP1) (WSXCSXXCG),
which is thought to be implicated in the binding of sul-
fated glycoconjugates [70] and to be important for cell
adhesion. The position of five of the six cysteines con-
tained in this domain is conserved in other proteins (e.g.
properdine, F-spondine, circumsporozoid protein) which
contain a TSP1 repeat and are implicated in the interac-
tions of the cells with the ECM.
The presence of a TSP module in the CCN proteins sug-
gested that they might be involved in functional interac-
tions with components of the ECM or play a role in cell
adhesion. To elaborate, CCN3 physically interacts with
fibulin1C, a matricellular protein involved in attachment
[48]. CCN1 promotes adhesion, migration and mitogen-
esis of human skin fibroblasts, and adhesion of vascular
smooth muscle cells [71–74]. Additionally, CCN2
promotes primary human skin fibroblast adhesion [72].
In both case, these functions involve binding to cell sur-
face receptors – among which integrins and HSPG. CCN1
up-regulates expression of matrix metalloproteinases 1
and 3 [73] which promote matrix remodelling. The bind-
ing of CCN4 to sulfate proteoglycans decorin and bigly-
can mediates and modulates the interaction of CCN4 with
the surface of fibroblasts [75].
However, there is no indication as yet to assign a direct
role for the TSP1 module in the interaction of CCN pro-
teins with their substrate. The construction of recom-
binant CCN proteins lacking module 3 (our unpublished
results, and L. Lau personal communication) should be
informative. It will be particularly interesting to establish
whether the TSP1 module plays biological functions by
itself or in cooperation with other modules and whether
its intrinsic biological properties are modulated by its
association with other modules in the CCN proteins.
Recently, a variant CCN1 protein lacking the TSP1 mod-
ule, has been detected in serum-induced normal human
fibroblasts [76].
It is also of high interest that in the (A)9 repeat located at
the junction of the second and third module in CCN6, is
the target for frameshift mutations [77]. The resulting
truncated CCN6(A)8 protein is deprived of both module
III and IV. CCN6(A)8 was detected in 31% of colorectal
carcinomas with microsatellite instability (MSI) and in
21% of MSI-positive gastric carcinomas [78]. These obser-
vations reinforced the idea that the different CCN
modules can function individually and that alterations of
the CCN protein structure is associated with tumourigen-
esis [4].
Module IV (CT)
Module IV, also designated CT, is encoded by exon5. It is
the less conserved of the four domains at the level of
nucleotide sequence, but it appears to be critical for sev-
eral of the biological functions attributed to the CCN pro-
teins. Module IV resembles the CT domain of several
extracellular protein including, Von Willebrand's factor
and mucins. Sequences similarities to Heparin-binding
motifs are also found within this domain [6].
Within the CT module, six cysteines form a structure
known as "cystin knot", which was implicated in the dim-
erisation of growth factors such as TGF-β, PDGF, and
Nerve Growth Factor (NGF), [79]. The presence of a cystin
knot in the CCN proteins might allow both homotypic
and heterotypic interactions with proteins containing a
similar structure. Dimerisation has not been conclusively
demonstrated for any of the CCN proteins to date, but it
has been shown that module IV is sufficient to permit the
interaction of CCN3 with CCN2 in the two hybrid system
and by GST pull down assay [57].
The CT domain is sufficient to allow interaction of CCN3
with Fibulin 1C, and Notch1 [57,58]. In CCN2, it is suffi-
cient to mediate cell adhesion in a divalent cation- and
heparin-dependent way [80]. Similarly, deletion of the CT
module in CCN1 abrogates its capacity to stimulate
integrin-dependent adhesion of fibroblasts [73]. There-
fore, it seems that the CT module may be critical for the
control of cell adhesion. An isoform of CCN2 lacking the
CT domain (CTGF-L) is also expressed in human primary
osteoblasts, fibroblasts, ovary, testes, and heart [81]; how-
ever, not much is known about its biological activities.
In the CCN proteins, module IV is thought to act synergis-
tically with module II in the formation of the high
molecular species which have been detected with all CCN
proteins. Although there is no experimental data as yet
indicating that any of their biological properties are
dependent upon their ability to oligomerise, it is highly
probable that the absence of four cysteines in module II of
CCN6, and the absence of domainIV in CCN5 might alter
their oligomerisation capacity and confer on these two
proteins new biological properties.
Conclusion and perspectives
The bulk of data obtained thus far regarding the involve-
ment of the CCN protein in tumourigenensis reinforces
the idea that their biological properties might be depend-
ent upon the cellular context; thereby suggesting that they
may show opposite functions in different cell types. The
variety of proteins interacting with members of the CCN
family pointed out the complexity of the regulatory cir-
cuitry in which these proteins are acting.Page 12 of 15
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action of CCN proteins with integrins accounts for most
of their biological properties both in normal and patho-
logical conditions. In as much as the CCN3 protein was
shown a) to interact with several proteins playing key
roles in various signaling pathways, b) modulate cytosolic
ion concentrations, and c) regulate transcription; we
would like to broaden this view. Our current working
hypothesis is based on the assumption that the CCN pro-
teins are "docking" proteins permitting a coordinated
interaction of the various receptors and co-factors. The
multimodular structure of the CCN proteins provides the
basis for multiple interactions and for combinatorial
events; they are expected to vary greatly among tissues and
cell types from cellular generation to death. The adapta-
tive response of cells to complex environmental changes
requires a precise coordination of signalling pathways.
Our current knowledge put the CCN family of cell growth
regulators at a central place in the control of these funda-
mental biological processes.
Note
We follow in this manuscript the recommendations for a
unified nomenclature of the CCN proteins [82]
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